Global Bispecific Antibody Drug Market By Manufacturing (IgG-based bispecifics, ScFv – based, CD3 – based bispecifics); By Application (Cancer, Autoimmune Diseases, Infectious Diseases, Neurologic, Cardiometabolic Diseases, Others); By End-User (Hospitals, Research Institutions, Others); By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
Global bispecific antibody drug market was valued at US$ 14.56 Bn in 2021, growing at an estimated CAGR of 16.79% over the forecast period. Healthcare industry, probably is the only industry which has grown exponentially over the last several years. The medical sector has seriously made insane amount of progress courtesy of advanced technologies. As compared to traditional monoclonal antibodies, the latest next gen bispecific has been successful in building new ability to bind to multiple targets at one time. This market has very subtly prompted the scientists and medical researchers to understand and reap benefits for patients out of these drugs. Over the period of last few years, these bispecific antibody drugs have managed to clear multiple clinical evaluations for various kinds of cancer including those tumours that are likely to be malignant. Additionally these drugs are unique and are gathering recognition at an international level rapidly.
The recent COVID-19 pandemic impacted the global bispecific antibody drug market in a positive way. The people with existing morbidities were more vulnerable to the dreadful virus and the antibody treatment was seen as one of the solutions. This spiked up the demand for the bispecific antibodies, ultimately contributing to the demand of this market.
Manufacturing Technology Outlook
On the basis of the manufacturing technology, the global bispecific antibody drug market has been divided IgG-based bispecifics, ScFV-based bispecifics and CD3-based bispecifics. The number of people suffering from cancer are continuously rising due to consumption of carcinogenic products. The IgG-based bispecific antibody is being used for improved dual targeting in the prostate-specific membrane antigen-positive cancer. Meanwhile, the ScFV-based bispecifics antibodies are used most extensively and account for maximum revenue generated by this market.
Global Bispecific Antibody Drug Market Revenue & Forecast, (US$ Million), 2015 – 2030
Application Outlook
On the basis of application, the global bispecific antibody drug market has been segmented into cancer, autoimmune diseases, infectious diseases, neurologic diseases, cardiometabolic diseases and others. The cancer segment dominates in terms of market share. Unhealthy lifestyle, along with excessive consumption of carcinogenic products has resulted in surging number of cancer patients. Along with radiation and chemo-therapies, the antibody drug treatment is also considered as a way of treating this life-threatening ailment. The rise of infectious diseases post coronavirus will directly drive the growth of the global bispecific antibody drug market. Similarly, increased awareness about neurologic diseases is also contributing towards the growth of this market.
End User Outlook
The end-user segment of the global bispecific antibody drug market has been bifurcated into hospitals, research institutions and others. The adoption of bispecific antibody drug treatment is done at a rampant rate in several hospitals and medical institutes across the globe. On monetary basis, these hospitals are strong enough to treat multiple patients at the same time. Today many hospitals have dedicated cancer treatment centres which primarily focus on the treatment of this dreadful disease. Meanwhile, many research institutions are rapidly experimenting with the help of bispecific antibody drugs to seek ideal or accurate treatment for existing ailments like cancer and cardiovascular diseases. The more successful results, these institutes get, easier it is to get approvals from health regulators. Additionally, these research institutes are also working to create awareness about this new drug, which helps in adoption of this type of treatment.
Region Outlook
On the basis of region, in the global bispecific antibody drug market, the region of North America dominates in terms of market share. With the presence of bigger medical institutes and hospitals along with huge healthcare sector, this market generates most of its revenue from the countries like the United States, and Canada. Additionally awareness about the antibody drugs is higher and this also contributes to the growth of the market.
Competitive Landscape
The report provides both, qualitative and quantitative research of global bispecific antibody drug market as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contacts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the major players operating in the global bispecific antibody drug market are listed below:
- AbbVie Inc.
- Adimab, LLC
- Affimed GmbH
- Amgen Inc.
- AstraZeneca
- Biomunex
- Chugai Pharmaceutical Co., Ltd
- Creative- Biolabs
- Emergent BioSolutions Inc.
- F. Hoffmann-La Roche Ltd
- F-star Therapeutics Inc.
- Genentech USA, Inc.
- Genmab A/S
- MacroGenics, Inc.
- Merck KGaA
- Merus
- Pieris
- Zymeworks
- Other Market Participants
Global Bispecific Antibody Drug Market
By Manufacturing Technology
- IgG-based bispecifics
- ScFv-based bispecifics
- CD3-based bispecifics
By Application
- Cancer
- Autoimmune Diseases
- Infectious Diseases
- Neurologic Diseases
- Cardiometabolic Diseases
- Others
By End-User
- Hospitals
- Research Institutions
- Others
By Region
- North America
- U.S
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2020
1.2.2. Base
Year: 2021
1.2.3. Forecast
Years: 2022 – 2030
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Bispecific Antibody Drug Market
6. Market Synopsis:
Bispecific Antibody Drug Market
7. Bispecific Antibody Drug Market Analysis: Qualitative
Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Bispecific Antibody Drug Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Bispecific Antibody Drug Market
7.6. Porter’s Five Force Analysis
7.7. Impact of
Covid-19 on Bispecific Antibody Drug Market
8. Global Bispecific Antibody Drug Market Analysis and
Forecasts, 2022 – 2030
8.1. Overview
8.1.1. Global
Bispecific Antibody Drug Market Revenue (US$ Mn)
8.2. Global
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
8.2.1. IgG-based
bispecifics
8.2.1.1. Definition
8.2.1.2. Market
Estimation and Penetration, 2015 – 2021
8.2.1.3. Market
Forecast, 2022 – 2030
8.2.1.4. Compound
Annual Growth Rate (CAGR)
8.2.1.5. Regional
Bifurcation
8.2.1.5.1. North
America
8.2.1.5.1.1. Market
Estimation, 2015 – 2021
8.2.1.5.1.2. Market
Forecast, 2022 – 2030
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2015 – 2021
8.2.1.5.2.2. Market
Forecast, 2022 – 2030
8.2.1.5.3. Asia
Pacific
8.2.1.5.3.1. Market
Estimation, 2015 – 2021
8.2.1.5.3.2. Market
Forecast, 2022 – 2030
8.2.1.5.4. Middle
East and Africa
8.2.1.5.4.1. Market
Estimation, 2015 – 2021
8.2.1.5.4.2. Market
Forecast, 2022 – 2030
8.2.1.5.5. Latin
America
8.2.1.5.5.1. Market
Estimation, 2015 – 2021
8.2.1.5.5.2. Market
Forecast, 2022 – 2030
8.2.2. ScFv-based
bispecifics
8.2.2.1. Definition
8.2.2.2. Market
Estimation and Penetration, 2015 – 2021
8.2.2.3. Market
Forecast, 2022 – 2030
8.2.2.4. Compound
Annual Growth Rate (CAGR)
8.2.2.5. Regional
Bifurcation
8.2.2.5.1. North
America
8.2.2.5.1.1. Market
Estimation, 2015 – 2021
8.2.2.5.1.2. Market
Forecast, 2022 – 2030
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 – 2021
8.2.2.5.2.2. Market
Forecast, 2022 – 2030
8.2.2.5.3. Asia
Pacific
8.2.2.5.3.1. Market
Estimation, 2015 – 2021
8.2.2.5.3.2. Market
Forecast, 2022 – 2030
8.2.2.5.4. Middle
East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 – 2021
8.2.2.5.4.2. Market
Forecast, 2022 – 2030
8.2.2.5.5. Latin
America
8.2.2.5.5.1. Market
Estimation, 2015 – 2021
8.2.2.5.5.2. Market
Forecast, 2022 – 2030
8.2.3. ScFv-based
bispecifics
8.2.3.1. Definition
8.2.3.2. Market
Estimation and Penetration, 2015 – 2021
8.2.3.3. Market
Forecast, 2022 – 2030
8.2.3.4. Compound
Annual Growth Rate (CAGR)
8.2.3.5. Regional
Bifurcation
8.2.3.5.1. North
America
8.2.3.5.1.1. Market
Estimation, 2015 – 2021
8.2.3.5.1.2. Market
Forecast, 2022 – 2030
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2015 – 2021
8.2.3.5.2.2. Market
Forecast, 2022 – 2030
8.2.3.5.3. Asia
Pacific
8.2.3.5.3.1. Market
Estimation, 2015 – 2021
8.2.3.5.3.2. Market
Forecast, 2022 – 2030
8.2.3.5.4. Middle
East and Africa
8.2.3.5.4.1. Market
Estimation, 2015 – 2021
8.2.3.5.4.2. Market
Forecast, 2022 – 2030
8.2.3.5.5. Latin
America
8.2.3.5.5.1. Market
Estimation, 2015 – 2021
8.2.3.5.5.2. Market
Forecast, 2022 – 2030
8.3. Key
Segment for Channeling Investments
8.3.1. By
Manufacturing Technology
9. Global Bispecific Antibody Drug Market Analysis and
Forecasts, 2022 – 2030
9.1. Overview
9.2. Global
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By Application
9.2.1. Cancer
9.2.1.1. Definition
9.2.1.2. Market
Estimation and Penetration, 2015 – 2021
9.2.1.3. Market
Forecast, 2022 – 2030
9.2.1.4. Compound
Annual Growth Rate (CAGR)
9.2.1.5. Regional
Bifurcation
9.2.1.5.1. North
America
9.2.1.5.1.1. Market
Estimation, 2015 – 2021
9.2.1.5.1.2. Market
Forecast, 2022 – 2030
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2015 – 2021
9.2.1.5.2.2. Market
Forecast, 2022 – 2030
9.2.1.5.3. Asia
Pacific
9.2.1.5.3.1. Market
Estimation, 2015 – 2021
9.2.1.5.3.2. Market
Forecast, 2022 – 2030
9.2.1.5.4. Middle
East and Africa
9.2.1.5.4.1. Market
Estimation, 2015 – 2021
9.2.1.5.4.2. Market
Forecast, 2022 – 2030
9.2.1.5.5. Latin
America
9.2.1.5.5.1. Market
Estimation, 2015 – 2021
9.2.1.5.5.2. Market
Forecast, 2022 – 2030
9.2.2. Autoimmune
Diseases
9.2.2.1. Definition
9.2.2.2. Market
Estimation and Penetration, 2015 – 2021
9.2.2.3. Market
Forecast, 2022 – 2030
9.2.2.4. Compound
Annual Growth Rate (CAGR)
9.2.2.5. Regional
Bifurcation
9.2.2.5.1. North
America
9.2.2.5.1.1. Market
Estimation, 2015 – 2021
9.2.2.5.1.2. Market
Forecast, 2022 – 2030
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 – 2021
9.2.2.5.2.2. Market
Forecast, 2022 – 2030
9.2.2.5.3. Asia
Pacific
9.2.2.5.3.1. Market
Estimation, 2015 – 2021
9.2.2.5.3.2. Market
Forecast, 2022 – 2030
9.2.2.5.4. Middle
East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 – 2021
9.2.2.5.4.2. Market
Forecast, 2022 – 2030
9.2.2.5.5. Latin
America
9.2.2.5.5.1. Market
Estimation, 2015 – 2021
9.2.2.5.5.2. Market
Forecast, 2022 – 2030
9.2.3. Infectious
Diseases
9.2.3.1. Definition
9.2.3.2. Market
Estimation and Penetration, 2015 – 2021
9.2.3.3. Market
Forecast, 2022 – 2030
9.2.3.4. Compound
Annual Growth Rate (CAGR)
9.2.3.5. Regional
Bifurcation
9.2.3.5.1. North
America
9.2.3.5.1.1. Market
Estimation, 2015 – 2021
9.2.3.5.1.2. Market
Forecast, 2022 – 2030
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2015 – 2021
9.2.3.5.2.2. Market
Forecast, 2022 – 2030
9.2.3.5.3. Asia
Pacific
9.2.3.5.3.1. Market
Estimation, 2015 – 2021
9.2.3.5.3.2. Market
Forecast, 2022 – 2030
9.2.3.5.4. Middle
East and Africa
9.2.3.5.4.1. Market
Estimation, 2015 – 2021
9.2.3.5.4.2. Market
Forecast, 2022 – 2030
9.2.3.5.5. Latin
America
9.2.3.5.5.1. Market
Estimation, 2015 – 2021
9.2.3.5.5.2. Market
Forecast, 2022 – 2030
9.2.4. Neurologic
Diseases
9.2.4.1. Definition
9.2.4.2. Market
Estimation and Penetration, 2015 – 2021
9.2.4.3. Market
Forecast, 2022 – 2030
9.2.4.4. Compound
Annual Growth Rate (CAGR)
9.2.4.5. Regional
Bifurcation
9.2.4.5.1. North
America
9.2.4.5.1.1. Market
Estimation, 2015 – 2021
9.2.4.5.1.2. Market
Forecast, 2022 – 2030
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2015 – 2021
9.2.4.5.2.2. Market
Forecast, 2022 – 2030
9.2.4.5.3. Asia
Pacific
9.2.4.5.3.1. Market
Estimation, 2015 – 2021
9.2.4.5.3.2. Market
Forecast, 2022 – 2030
9.2.4.5.4. Middle
East and Africa
9.2.4.5.4.1. Market
Estimation, 2015 – 2021
9.2.4.5.4.2. Market
Forecast, 2022 – 2030
9.2.4.5.5. Latin
America
9.2.4.5.5.1. Market
Estimation, 2015 – 2021
9.2.4.5.5.2. Market
Forecast, 2022 – 2030
9.2.5. Cardiometabolic
Diseases
9.2.5.1. Definition
9.2.5.2. Market
Estimation and Penetration, 2015 – 2021
9.2.5.3. Market
Forecast, 2022 – 2030
9.2.5.4. Compound
Annual Growth Rate (CAGR)
9.2.5.5. Regional
Bifurcation
9.2.5.5.1. North
America
9.2.5.5.1.1. Market
Estimation, 2015 – 2021
9.2.5.5.1.2. Market
Forecast, 2022 – 2030
9.2.5.5.2. Europe
9.2.5.5.2.1. Market
Estimation, 2015 – 2021
9.2.5.5.2.2. Market
Forecast, 2022 – 2030
9.2.5.5.3. Asia
Pacific
9.2.5.5.3.1. Market
Estimation, 2015 – 2021
9.2.5.5.3.2. Market
Forecast, 2022 – 2030
9.2.5.5.4. Middle
East and Africa
9.2.5.5.4.1. Market
Estimation, 2015 – 2021
9.2.5.5.4.2. Market
Forecast, 2022 – 2030
9.2.5.5.5. Latin
America
9.2.5.5.5.1. Market
Estimation, 2015 – 2021
9.2.5.5.5.2. Market
Forecast, 2022 – 2030
9.2.6. Others
9.2.6.1. Definition
9.2.6.2. Market
Estimation and Penetration, 2015 – 2021
9.2.6.3. Market
Forecast, 2022 – 2030
9.2.6.4. Compound
Annual Growth Rate (CAGR)
9.2.6.5. Regional
Bifurcation
9.2.6.5.1. North
America
9.2.6.5.1.1. Market
Estimation, 2015 – 2021
9.2.6.5.1.2. Market
Forecast, 2022 – 2030
9.2.6.5.2. Europe
9.2.6.5.2.1. Market
Estimation, 2015 – 2021
9.2.6.5.2.2. Market
Forecast, 2022 – 2030
9.2.6.5.3. Asia
Pacific
9.2.6.5.3.1. Market
Estimation, 2015 – 2021
9.2.6.5.3.2. Market
Forecast, 2022 – 2030
9.2.6.5.4. Middle
East and Africa
9.2.6.5.4.1. Market
Estimation, 2015 – 2021
9.2.6.5.4.2. Market
Forecast, 2022 – 2030
9.2.6.5.5. Latin
America
9.2.6.5.5.1. Market
Estimation, 2015 – 2021
9.2.6.5.5.2. Market
Forecast, 2022 – 2030
9.3. Key
Segment for Channeling Investments
9.3.1. By
Application
10. Global Bispecific Antibody Drug Market Analysis and
Forecasts, 2022 – 2030
10.1. Overview
10.2. Global
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By End-User
10.2.1. Hospitals
10.2.1.1. Definition
10.2.1.2. Market
Estimation and Penetration, 2015 – 2021
10.2.1.3. Market
Forecast, 2022 – 2030
10.2.1.4. Compound
Annual Growth Rate (CAGR)
10.2.1.5. Regional
Bifurcation
10.2.1.5.1. North
America
10.2.1.5.1.1. Market
Estimation, 2015 – 2021
10.2.1.5.1.2. Market
Forecast, 2022 – 2030
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2015 – 2021
10.2.1.5.2.2. Market
Forecast, 2022 – 2030
10.2.1.5.3. Asia
Pacific
10.2.1.5.3.1. Market
Estimation, 2015 – 2021
10.2.1.5.3.2. Market
Forecast, 2022 – 2030
10.2.1.5.4. Middle
East and Africa
10.2.1.5.4.1. Market
Estimation, 2015 – 2021
10.2.1.5.4.2. Market
Forecast, 2022 – 2030
10.2.1.5.5. Latin
America
10.2.1.5.5.1. Market
Estimation, 2015 – 2021
10.2.1.5.5.2. Market
Forecast, 2022 – 2030
10.2.2. Research
Institutions
10.2.2.1. Definition
10.2.2.2. Market
Estimation and Penetration, 2015 – 2021
10.2.2.3. Market
Forecast, 2022 – 2030
10.2.2.4. Compound
Annual Growth Rate (CAGR)
10.2.2.5. Regional
Bifurcation
10.2.2.5.1. North
America
10.2.2.5.1.1. Market
Estimation, 2015 – 2021
10.2.2.5.1.2. Market
Forecast, 2022 – 2030
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2015 – 2021
10.2.2.5.2.2. Market
Forecast, 2022 – 2030
10.2.2.5.3. Asia
Pacific
10.2.2.5.3.1. Market
Estimation, 2015 – 2021
10.2.2.5.3.2. Market
Forecast, 2022 – 2030
10.2.2.5.4. Middle
East and Africa
10.2.2.5.4.1. Market
Estimation, 2015 – 2021
10.2.2.5.4.2. Market
Forecast, 2022 – 2030
10.2.2.5.5. Latin
America
10.2.2.5.5.1. Market
Estimation, 2015 – 2021
10.2.2.5.5.2. Market
Forecast, 2022 – 2030
10.2.3. Others
10.2.3.1. Definition
10.2.3.2. Market
Estimation and Penetration, 2015 – 2021
10.2.3.3. Market
Forecast, 2022 – 2030
10.2.3.4. Compound
Annual Growth Rate (CAGR)
10.2.3.5. Regional
Bifurcation
10.2.3.5.1. North
America
10.2.3.5.1.1. Market
Estimation, 2015 – 2021
10.2.3.5.1.2. Market
Forecast, 2022 – 2030
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2015 – 2021
10.2.3.5.2.2. Market
Forecast, 2022 – 2030
10.2.3.5.3. Asia
Pacific
10.2.3.5.3.1. Market
Estimation, 2015 – 2021
10.2.3.5.3.2. Market
Forecast, 2022 – 2030
10.2.3.5.4. Middle
East and Africa
10.2.3.5.4.1. Market
Estimation, 2015 – 2021
10.2.3.5.4.2. Market
Forecast, 2022 – 2030
10.2.3.5.5. Latin
America
10.2.3.5.5.1. Market
Estimation, 2015 – 2021
10.2.3.5.5.2. Market
Forecast, 2022 – 2030
10.3. Key
Segment for Channeling Investments
10.3.1. By
End-User
11. North America Bispecific Antibody Drug Market Analysis and
Forecasts, 2022 - 2030
11.1. Overview
11.1.1. North
America Bispecific Antibody Drug Market Revenue (US$ Mn)
11.2. North
America Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
11.2.1. IgG-based
bispecifics
11.2.2. ScFv-based
bispecifics
11.2.3. ScFv-based
bispecifics
11.3. North
America Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Application
11.3.1. Cancer
11.3.2. Autoimmune
Diseases
11.3.3. Infectious
Diseases
11.3.4. Neurologic
Diseases
11.3.5. Cardiometabolic
Diseases
11.3.6. Others
11.4. North
America Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
End-User
11.4.1. Hospitals
11.4.2. Research
Institutions
11.4.3. Others
11.5. North
America Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Country
11.5.1. U.S
11.5.1.1. U.S
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
11.5.1.1.1. IgG-based
bispecifics
11.5.1.1.2. ScFv-based
bispecifics
11.5.1.1.3. ScFv-based
bispecifics
11.5.1.2. U.S
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By Application
11.5.1.2.1. Cancer
11.5.1.2.2. Autoimmune
Diseases
11.5.1.2.3. Infectious
Diseases
11.5.1.2.4. Neurologic
Diseases
11.5.1.2.5. Cardiometabolic
Diseases
11.5.1.2.6. Others
11.5.1.3. U.S
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By End-User
11.5.1.3.1. Hospitals
11.5.1.3.2. Research
Institutions
11.5.1.3.3. Others
11.5.2. Canada
11.5.2.1. Canada
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
11.5.2.1.1. IgG-based
bispecifics
11.5.2.1.2. ScFv-based
bispecifics
11.5.2.1.3. ScFv-based
bispecifics
11.5.2.2. Canada
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By Application
11.5.2.2.1. Cancer
11.5.2.2.2. Autoimmune
Diseases
11.5.2.2.3. Infectious
Diseases
11.5.2.2.4. Neurologic
Diseases
11.5.2.2.5. Cardiometabolic
Diseases
11.5.2.2.6. Others
11.5.2.3. Canada
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By End-User
11.5.2.3.1. Hospitals
11.5.2.3.2. Research
Institutions
11.5.2.3.3. Others
11.5.3. Mexico
11.5.3.1. Mexico
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
11.5.3.1.1. IgG-based
bispecifics
11.5.3.1.2. ScFv-based
bispecifics
11.5.3.1.3. ScFv-based
bispecifics
11.5.3.2. Mexico
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By Application
11.5.3.2.1. Cancer
11.5.3.2.2. Autoimmune
Diseases
11.5.3.2.3. Infectious
Diseases
11.5.3.2.4. Neurologic
Diseases
11.5.3.2.5. Cardiometabolic
Diseases
11.5.3.2.6. Others
11.5.3.3. Mexico
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By End-User
11.5.3.3.1. Hospitals
11.5.3.3.2. Research
Institutions
11.5.3.3.3. Others
11.5.4. Rest of
North America
11.5.4.1. Rest
of North America Bispecific Antibody Drug Market Revenue (US$ Mn) and
Forecasts, By Manufacturing Technology
11.5.4.1.1. IgG-based
bispecifics
11.5.4.1.2. ScFv-based
bispecifics
11.5.4.1.3. ScFv-based
bispecifics
11.5.4.2. Rest
of North America Bispecific Antibody Drug Market Revenue (US$ Mn) and
Forecasts, By Application
11.5.4.2.1. Cancer
11.5.4.2.2. Autoimmune
Diseases
11.5.4.2.3. Infectious
Diseases
11.5.4.2.4. Neurologic
Diseases
11.5.4.2.5. Cardiometabolic
Diseases
11.5.4.2.6. Others
11.5.4.3. Rest
of North America Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts,
By End-User
11.5.4.3.1. Hospitals
11.5.4.3.2. Research
Institutions
11.5.4.3.3. Others
11.6. Key
Segment for Channeling Investments
11.6.1. By
Country
11.6.2. By
Manufacturing Technology
11.6.3. By
Application
11.6.4. By
End-User
12. Europe Bispecific Antibody Drug Market Analysis and
Forecasts, 2022 - 2030
12.1. Overview
12.1.1. Europe
Bispecific Antibody Drug Market Revenue (US$ Mn)
12.2. Europe
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
12.2.1. IgG-based
bispecifics
12.2.2. ScFv-based
bispecifics
12.2.3. ScFv-based
bispecifics
12.3. Europe
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By Application
12.3.1. Cancer
12.3.2. Autoimmune
Diseases
12.3.3. Infectious
Diseases
12.3.4. Neurologic
Diseases
12.3.5. Cardiometabolic
Diseases
12.3.6. Others
12.4. Europe
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By End-User
12.4.1. Hospitals
12.4.2. Research
Institutions
12.4.3. Others
12.5. Europe
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By Country
12.5.1. France
12.5.1.1. France
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
12.5.1.1.1. IgG-based
bispecifics
12.5.1.1.2. ScFv-based
bispecifics
12.5.1.1.3. ScFv-based
bispecifics
12.5.1.2. France
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By Application
12.5.1.2.1. Cancer
12.5.1.2.2. Autoimmune
Diseases
12.5.1.2.3. Infectious
Diseases
12.5.1.2.4. Neurologic
Diseases
12.5.1.2.5. Cardiometabolic
Diseases
12.5.1.2.6. Others
12.5.1.3. France
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By End-User
12.5.1.3.1. Hospitals
12.5.1.3.2. Research
Institutions
12.5.1.3.3. Others
12.5.2. The UK
12.5.2.1. The
UK Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
12.5.2.1.1. IgG-based
bispecifics
12.5.2.1.2. ScFv-based
bispecifics
12.5.2.1.3. ScFv-based
bispecifics
12.5.2.2. The
UK Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Application
12.5.2.2.1. Cancer
12.5.2.2.2. Autoimmune
Diseases
12.5.2.2.3. Infectious
Diseases
12.5.2.2.4. Neurologic
Diseases
12.5.2.2.5. Cardiometabolic
Diseases
12.5.2.2.6. Others
12.5.2.3. The
UK Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By End-User
12.5.2.3.1. Hospitals
12.5.2.3.2. Research
Institutions
12.5.2.3.3. Others
12.5.3. Spain
12.5.3.1. Spain
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
12.5.3.1.1. IgG-based
bispecifics
12.5.3.1.2. ScFv-based
bispecifics
12.5.3.1.3. ScFv-based
bispecifics
12.5.3.2. Spain
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By Application
12.5.3.2.1. Cancer
12.5.3.2.2. Autoimmune
Diseases
12.5.3.2.3. Infectious
Diseases
12.5.3.2.4. Neurologic
Diseases
12.5.3.2.5. Cardiometabolic
Diseases
12.5.3.2.6. Others
12.5.3.3. Spain
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By End-User
12.5.3.3.1. Hospitals
12.5.3.3.2. Research
Institutions
12.5.3.3.3. Others
12.5.4. Germany
12.5.4.1. Germany
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
12.5.4.1.1. IgG-based
bispecifics
12.5.4.1.2. ScFv-based
bispecifics
12.5.4.1.3. ScFv-based
bispecifics
12.5.4.2. Germany
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By Application
12.5.4.2.1. Cancer
12.5.4.2.2. Autoimmune
Diseases
12.5.4.2.3. Infectious
Diseases
12.5.4.2.4. Neurologic
Diseases
12.5.4.2.5. Cardiometabolic
Diseases
12.5.4.2.6. Others
12.5.4.3. Germany
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By End-User
12.5.4.3.1. Hospitals
12.5.4.3.2. Research
Institutions
12.5.4.3.3. Others
12.5.5. Italy
12.5.5.1. Italy
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
12.5.5.1.1. IgG-based
bispecifics
12.5.5.1.2. ScFv-based
bispecifics
12.5.5.1.3. ScFv-based
bispecifics
12.5.5.2. Italy
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By Application
12.5.5.2.1. Cancer
12.5.5.2.2. Autoimmune
Diseases
12.5.5.2.3. Infectious
Diseases
12.5.5.2.4. Neurologic
Diseases
12.5.5.2.5. Cardiometabolic
Diseases
12.5.5.2.6. Others
12.5.5.3. Italy
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By End-User
12.5.5.3.1. Hospitals
12.5.5.3.2. Research
Institutions
12.5.5.3.3. Others
12.5.6. Nordic
Countries
12.5.6.1. Nordic
Countries Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
12.5.6.1.1. IgG-based
bispecifics
12.5.6.1.2. ScFv-based
bispecifics
12.5.6.1.3. ScFv-based
bispecifics
12.5.6.2. Nordic
Countries Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Application
12.5.6.2.1. Cancer
12.5.6.2.2. Autoimmune
Diseases
12.5.6.2.3. Infectious
Diseases
12.5.6.2.4. Neurologic
Diseases
12.5.6.2.5. Cardiometabolic
Diseases
12.5.6.2.6. Others
12.5.6.3. Nordic
Countries Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
End-User
12.5.6.3.1. Hospitals
12.5.6.3.2. Research
Institutions
12.5.6.3.3. Others
12.5.6.4. Nordic
Countries Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Country
12.5.6.4.1. Denmark
12.5.6.4.2. Finland
12.5.6.4.3. Iceland
12.5.6.4.4. Sweden
12.5.6.4.5. Norway
12.5.7. Benelux
Union
12.5.7.1. Benelux
Union Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
12.5.7.1.1. IgG-based
bispecifics
12.5.7.1.2. ScFv-based
bispecifics
12.5.7.1.3. ScFv-based
bispecifics
12.5.7.2. Benelux
Union Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Application
12.5.7.2.1. Cancer
12.5.7.2.2. Autoimmune
Diseases
12.5.7.2.3. Infectious
Diseases
12.5.7.2.4. Neurologic
Diseases
12.5.7.2.5. Cardiometabolic
Diseases
12.5.7.2.6. Others
12.5.7.3. Benelux
Union Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
End-User
12.5.7.3.1. Hospitals
12.5.7.3.2. Research
Institutions
12.5.7.3.3. Others
12.5.7.4. Benelux
Union Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Country
12.5.7.4.1. Belgium
12.5.7.4.2. The
Netherlands
12.5.7.4.3. Luxembourg
12.5.8. Rest of
Europe
12.5.8.1. Rest
of Europe Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
12.5.8.1.1. IgG-based
bispecifics
12.5.8.1.2. ScFv-based
bispecifics
12.5.8.1.3. ScFv-based
bispecifics
12.5.8.2. Rest
of Europe Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By Application
12.5.8.2.1. Cancer
12.5.8.2.2. Autoimmune
Diseases
12.5.8.2.3. Infectious
Diseases
12.5.8.2.4. Neurologic
Diseases
12.5.8.2.5. Cardiometabolic
Diseases
12.5.8.2.6. Others
12.5.8.3. Rest
of Europe Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
End-User
12.5.8.3.1. Hospitals
12.5.8.3.2. Research
Institutions
12.5.8.3.3. Others
12.6. Key
Segment for Channeling Investments
12.6.1. By
Country
12.6.2. By
Manufacturing Technology
12.6.3. By
Application
12.6.4. By
End-User
13. Asia Pacific Bispecific Antibody Drug Market Analysis and
Forecasts, 2022 - 2030
13.1. Overview
13.1.1. Asia
Pacific Bispecific Antibody Drug Market Revenue (US$ Mn)
13.2. Asia
Pacific Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
13.2.1. IgG-based
bispecifics
13.2.2. ScFv-based
bispecifics
13.2.3. ScFv-based
bispecifics
13.3. Asia
Pacific Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Application
13.3.1. Cancer
13.3.2. Autoimmune
Diseases
13.3.3. Infectious
Diseases
13.3.4. Neurologic
Diseases
13.3.5. Cardiometabolic
Diseases
13.3.6. Others
13.4. Asia
Pacific Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
End-User
13.4.1. Hospitals
13.4.2. Research
Institutions
13.4.3. Others
13.5. Asia
Pacific Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Country
13.5.1. China
13.5.1.1. China
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
13.5.1.1.1. IgG-based
bispecifics
13.5.1.1.2. ScFv-based
bispecifics
13.5.1.1.3. ScFv-based
bispecifics
13.5.1.2. China
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By Application
13.5.1.2.1. Cancer
13.5.1.2.2. Autoimmune
Diseases
13.5.1.2.3. Infectious
Diseases
13.5.1.2.4. Neurologic
Diseases
13.5.1.2.5. Cardiometabolic
Diseases
13.5.1.2.6. Others
13.5.1.3. China
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By End-User
13.5.1.3.1. Hospitals
13.5.1.3.2. Research
Institutions
13.5.1.3.3. Others
13.5.2. Japan
13.5.2.1. Japan
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
13.5.2.1.1. IgG-based
bispecifics
13.5.2.1.2. ScFv-based
bispecifics
13.5.2.1.3. ScFv-based
bispecifics
13.5.2.2. Japan
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By Application
13.5.2.2.1. Cancer
13.5.2.2.2. Autoimmune
Diseases
13.5.2.2.3. Infectious
Diseases
13.5.2.2.4. Neurologic
Diseases
13.5.2.2.5. Cardiometabolic
Diseases
13.5.2.2.6. Others
13.5.2.3. Japan
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By End-User
13.5.2.3.1. Hospitals
13.5.2.3.2. Research
Institutions
13.5.2.3.3. Others
13.5.3. India
13.5.3.1. India
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
13.5.3.1.1. IgG-based
bispecifics
13.5.3.1.2. ScFv-based
bispecifics
13.5.3.1.3. ScFv-based
bispecifics
13.5.3.2. India
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By Application
13.5.3.2.1. Cancer
13.5.3.2.2. Autoimmune
Diseases
13.5.3.2.3. Infectious
Diseases
13.5.3.2.4. Neurologic
Diseases
13.5.3.2.5. Cardiometabolic
Diseases
13.5.3.2.6. Others
13.5.3.3. India
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By End-User
13.5.3.3.1. Hospitals
13.5.3.3.2. Research
Institutions
13.5.3.3.3. Others
13.5.4. New
Zealand
13.5.4.1. New
Zealand Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
13.5.4.1.1. IgG-based
bispecifics
13.5.4.1.2. ScFv-based
bispecifics
13.5.4.1.3. ScFv-based
bispecifics
13.5.4.2. New
Zealand Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Application
13.5.4.2.1. Cancer
13.5.4.2.2. Autoimmune
Diseases
13.5.4.2.3. Infectious
Diseases
13.5.4.2.4. Neurologic
Diseases
13.5.4.2.5. Cardiometabolic
Diseases
13.5.4.2.6. Others
13.5.4.3. New
Zealand Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
End-User
13.5.4.3.1. Hospitals
13.5.4.3.2. Research
Institutions
13.5.4.3.3. Others
13.5.5. Australia
13.5.5.1. Australia
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
13.5.5.1.1. IgG-based
bispecifics
13.5.5.1.2. ScFv-based
bispecifics
13.5.5.1.3. ScFv-based
bispecifics
13.5.5.2. Australia
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By Application
13.5.5.2.1. Cancer
13.5.5.2.2. Autoimmune
Diseases
13.5.5.2.3. Infectious
Diseases
13.5.5.2.4. Neurologic
Diseases
13.5.5.2.5. Cardiometabolic
Diseases
13.5.5.2.6. Others
13.5.5.3. Australia
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By End-User
13.5.5.3.1. Hospitals
13.5.5.3.2. Research
Institutions
13.5.5.3.3. Others
13.5.6. South
Korea
13.5.6.1. South
Korea Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
13.5.6.1.1. IgG-based
bispecifics
13.5.6.1.2. ScFv-based
bispecifics
13.5.6.1.3. ScFv-based
bispecifics
13.5.6.2. South
Korea Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Application
13.5.6.2.1. Cancer
13.5.6.2.2. Autoimmune
Diseases
13.5.6.2.3. Infectious
Diseases
13.5.6.2.4. Neurologic
Diseases
13.5.6.2.5. Cardiometabolic
Diseases
13.5.6.2.6. Others
13.5.6.3. South
Korea Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
End-User
13.5.6.3.1. Hospitals
13.5.6.3.2. Research
Institutions
13.5.6.3.3. Others
13.5.7. Southeast
Asia
13.5.7.1. Southeast
Asia Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
13.5.7.1.1. IgG-based
bispecifics
13.5.7.1.2. ScFv-based
bispecifics
13.5.7.1.3. ScFv-based
bispecifics
13.5.7.2. Southeast
Asia Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Application
13.5.7.2.1. Cancer
13.5.7.2.2. Autoimmune
Diseases
13.5.7.2.3. Infectious
Diseases
13.5.7.2.4. Neurologic
Diseases
13.5.7.2.5. Cardiometabolic
Diseases
13.5.7.2.6. Others
13.5.7.3. Southeast
Asia Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
End-User
13.5.7.3.1. Hospitals
13.5.7.3.2. Research
Institutions
13.5.7.3.3. Others
13.5.7.4. Southeast
Asia Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By Country
13.5.7.4.1. Indonesia
13.5.7.4.2. Thailand
13.5.7.4.3. Malaysia
13.5.7.4.4. Singapore
13.5.7.4.5. Rest
of Southeast Asia
13.5.8. Rest of
Asia Pacific
13.5.8.1. Rest
of Asia Pacific Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts,
By Manufacturing Technology
13.5.8.1.1. IgG-based
bispecifics
13.5.8.1.2. ScFv-based
bispecifics
13.5.8.1.3. ScFv-based
bispecifics
13.5.8.2. Rest
of Asia Pacific Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts,
By Application
13.5.8.2.1. Cancer
13.5.8.2.2. Autoimmune
Diseases
13.5.8.2.3. Infectious
Diseases
13.5.8.2.4. Neurologic
Diseases
13.5.8.2.5. Cardiometabolic
Diseases
13.5.8.2.6. Others
13.5.8.3. Rest
of Asia Pacific Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts,
By End-User
13.5.8.3.1. Hospitals
13.5.8.3.2. Research
Institutions
13.5.8.3.3. Others
13.6. Key
Segment for Channeling Investments
13.6.1. By
Country
13.6.2. By
Manufacturing Technology
13.6.3. By
Application
13.6.4. By
End-User
14. Middle East and Africa Bispecific Antibody Drug Market
Analysis and Forecasts, 2022 - 2030
14.1. Overview
14.1.1. Middle
East and Africa Bispecific Antibody Drug Market Revenue (US$ Mn)
14.2. Middle
East and Africa Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts,
By Manufacturing Technology
14.2.1. IgG-based
bispecifics
14.2.2. ScFv-based
bispecifics
14.2.3. ScFv-based
bispecifics
14.3. Middle
East and Africa Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts,
By Application
14.3.1. Cancer
14.3.2. Autoimmune
Diseases
14.3.3. Infectious
Diseases
14.3.4. Neurologic
Diseases
14.3.5. Cardiometabolic
Diseases
14.3.6. Others
14.4. Middle
East and Africa Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts,
By End-User
14.4.1. Hospitals
14.4.2. Research
Institutions
14.4.3. Others
14.5. Middle
East and Africa Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts,
By Country
14.5.1. Saudi
Arabia
14.5.1.1. Saudi
Arabia Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
14.5.1.1.1. IgG-based
bispecifics
14.5.1.1.2. ScFv-based
bispecifics
14.5.1.1.3. ScFv-based
bispecifics
14.5.1.2. Saudi
Arabia Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Application
14.5.1.2.1. Cancer
14.5.1.2.2. Autoimmune
Diseases
14.5.1.2.3. Infectious
Diseases
14.5.1.2.4. Neurologic
Diseases
14.5.1.2.5. Cardiometabolic
Diseases
14.5.1.2.6. Others
14.5.1.3. Saudi
Arabia Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
End-User
14.5.1.3.1. Hospitals
14.5.1.3.2. Research
Institutions
14.5.1.3.3. Others
14.5.2. UAE
14.5.2.1. UAE
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
14.5.2.1.1. IgG-based
bispecifics
14.5.2.1.2. ScFv-based
bispecifics
14.5.2.1.3. ScFv-based
bispecifics
14.5.2.2. UAE
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By Application
14.5.2.2.1. Cancer
14.5.2.2.2. Autoimmune
Diseases
14.5.2.2.3. Infectious
Diseases
14.5.2.2.4. Neurologic
Diseases
14.5.2.2.5. Cardiometabolic
Diseases
14.5.2.2.6. Others
14.5.2.3. UAE
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By End-User
14.5.2.3.1. Hospitals
14.5.2.3.2. Research
Institutions
14.5.2.3.3. Others
14.5.3. Egypt
14.5.3.1. Egypt
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
14.5.3.1.1. IgG-based
bispecifics
14.5.3.1.2. ScFv-based
bispecifics
14.5.3.1.3. ScFv-based
bispecifics
14.5.3.2. Egypt
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By Application
14.5.3.2.1. Cancer
14.5.3.2.2. Autoimmune
Diseases
14.5.3.2.3. Infectious
Diseases
14.5.3.2.4. Neurologic
Diseases
14.5.3.2.5. Cardiometabolic
Diseases
14.5.3.2.6. Others
14.5.3.3. Egypt
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By End-User
14.5.3.3.1. Hospitals
14.5.3.3.2. Research
Institutions
14.5.3.3.3. Others
14.5.4. Kuwait
14.5.4.1. Kuwait
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
14.5.4.1.1. IgG-based
bispecifics
14.5.4.1.2. ScFv-based
bispecifics
14.5.4.1.3. ScFv-based
bispecifics
14.5.4.2. Kuwait
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By Application
14.5.4.2.1. Cancer
14.5.4.2.2. Autoimmune
Diseases
14.5.4.2.3. Infectious
Diseases
14.5.4.2.4. Neurologic
Diseases
14.5.4.2.5. Cardiometabolic
Diseases
14.5.4.2.6. Others
14.5.4.3. Kuwait
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By End-User
14.5.4.3.1. Hospitals
14.5.4.3.2. Research
Institutions
14.5.4.3.3. Others
14.5.5. South
Africa
14.5.5.1. South
Africa Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
14.5.5.1.1. IgG-based
bispecifics
14.5.5.1.2. ScFv-based
bispecifics
14.5.5.1.3. ScFv-based
bispecifics
14.5.5.2. South
Africa Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Application
14.5.5.2.1. Cancer
14.5.5.2.2. Autoimmune
Diseases
14.5.5.2.3. Infectious
Diseases
14.5.5.2.4. Neurologic
Diseases
14.5.5.2.5. Cardiometabolic
Diseases
14.5.5.2.6. Others
14.5.5.3. South
Africa Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
End-User
14.5.5.3.1. Hospitals
14.5.5.3.2. Research
Institutions
14.5.5.3.3. Others
14.5.6. Rest of
Middle East & Africa
14.5.6.1. Rest
of Middle East & Africa Bispecific Antibody Drug Market Revenue (US$ Mn)
and Forecasts, By Manufacturing Technology
14.5.6.1.1. IgG-based
bispecifics
14.5.6.1.2. ScFv-based
bispecifics
14.5.6.1.3. ScFv-based
bispecifics
14.5.6.2. Rest
of Middle East & Africa Bispecific Antibody Drug Market Revenue (US$ Mn)
and Forecasts, By Application
14.5.6.2.1. Cancer
14.5.6.2.2. Autoimmune
Diseases
14.5.6.2.3. Infectious
Diseases
14.5.6.2.4. Neurologic
Diseases
14.5.6.2.5. Cardiometabolic
Diseases
14.5.6.2.6. Others
14.5.6.3. Rest
of Middle East & Africa Bispecific Antibody Drug Market Revenue (US$ Mn)
and Forecasts, By End-User
14.5.6.3.1. Hospitals
14.5.6.3.2. Research
Institutions
14.5.6.3.3. Others
14.6. Key
Segment for Channeling Investments
14.6.1. By
Country
14.6.2. By
Manufacturing Technology
14.6.3. By
Application
14.6.4. By
End-User
15. Latin America Bispecific Antibody Drug Market Analysis and
Forecasts, 2022 - 2030
15.1. Overview
15.1.1. Latin
America Bispecific Antibody Drug Market Revenue (US$ Mn)
15.2. Latin
America Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
15.2.1. IgG-based
bispecifics
15.2.2. ScFv-based
bispecifics
15.2.3. ScFv-based
bispecifics
15.3. Latin
America Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Application
15.3.1. Cancer
15.3.2. Autoimmune
Diseases
15.3.3. Infectious
Diseases
15.3.4. Neurologic
Diseases
15.3.5. Cardiometabolic
Diseases
15.3.6. Others
15.4. Latin
America Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
End-User
15.4.1. Hospitals
15.4.2. Research
Institutions
15.4.3. Others
15.5. Latin
America Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Country
15.5.1. Brazil
15.5.1.1. Brazil
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
15.5.1.1.1. IgG-based
bispecifics
15.5.1.1.2. ScFv-based
bispecifics
15.5.1.1.3. ScFv-based
bispecifics
15.5.1.2. Brazil
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By Application
15.5.1.2.1. Cancer
15.5.1.2.2. Autoimmune
Diseases
15.5.1.2.3. Infectious
Diseases
15.5.1.2.4. Neurologic
Diseases
15.5.1.2.5. Cardiometabolic
Diseases
15.5.1.2.6. Others
15.5.1.3. Brazil
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By End-User
15.5.1.3.1. Hospitals
15.5.1.3.2. Research
Institutions
15.5.1.3.3. Others
15.5.2. Argentina
15.5.2.1. Argentina
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By
Manufacturing Technology
15.5.2.1.1. IgG-based
bispecifics
15.5.2.1.2. ScFv-based
bispecifics
15.5.2.1.3. ScFv-based
bispecifics
15.5.2.2. Argentina
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By Application
15.5.2.2.1. Cancer
15.5.2.2.2. Autoimmune
Diseases
15.5.2.2.3. Infectious
Diseases
15.5.2.2.4. Neurologic
Diseases
15.5.2.2.5. Cardiometabolic
Diseases
15.5.2.2.6. Others
15.5.2.3. Argentina
Bispecific Antibody Drug Market Revenue (US$ Mn) and Forecasts, By End-User
15.5.2.3.1. Hospitals
15.5.2.3.2. Research
Institutions
15.5.2.3.3. Others
15.5.3. Rest of
Latin America
15.5.3.1. Rest
of Latin America Bispecific Antibody Drug Market Revenue (US$ Mn) and
Forecasts, By Manufacturing Technology
15.5.3.1.1. IgG-based
bispecifics
15.5.3.1.2. ScFv-based
bispecifics
15.5.3.1.3. ScFv-based
bispecifics
15.5.3.2. Rest
of Latin America Bispecific Antibody Drug Market Revenue (US$ Mn) and
Forecasts, By Application
15.5.3.2.1. Cancer
15.5.3.2.2. Autoimmune
Diseases
15.5.3.2.3. Infectious
Diseases
15.5.3.2.4. Neurologic
Diseases
15.5.3.2.5. Cardiometabolic
Diseases
15.5.3.2.6. Others
15.5.3.3. Rest
of Latin America Bispecific Antibody Drug Market Revenue (US$ Mn) and
Forecasts, By End-User
15.5.3.3.1. Hospitals
15.5.3.3.2. Research
Institutions
15.5.3.3.3. Others
15.6. Key
Segment for Channeling Investments
15.6.1. By
Country
15.6.2. By
Manufacturing Technology
15.6.3. By
Application
15.6.4. By
End-User
16. Competitive Benchmarking
16.1. Brand
Benchmarking
16.2. Market
Share Analysis, 2021
16.3. Global
Presence and Growth Strategies
16.3.1. Mergers
and Acquisitions
16.3.2. Product
Launches
16.3.3. Investments
Trends
16.3.4. R&D
Initiatives
17. Player Profiles
17.1. AbbVie
Inc.
17.1.1. Company
Details
17.1.2. Company
Overview
17.1.3. Product
Offerings
17.1.4. Key
Developments
17.1.5. Financial
Analysis
17.1.6. SWOT
Analysis
17.1.7. Business
Strategies
17.2. Adimab,
LLC
17.2.1. Company
Details
17.2.2. Company
Overview
17.2.3. Product
Offerings
17.2.4. Key
Developments
17.2.5. Financial
Analysis
17.2.6. SWOT
Analysis
17.2.7. Business
Strategies
17.3. Affimed
GmbH
17.3.1. Company
Details
17.3.2. Company
Overview
17.3.3. Product
Offerings
17.3.4. Key
Developments
17.3.5. Financial
Analysis
17.3.6. SWOT
Analysis
17.3.7. Business
Strategies
17.4. Amgen
Inc.
17.4.1. Company
Details
17.4.2. Company
Overview
17.4.3. Product
Offerings
17.4.4. Key
Developments
17.4.5. Financial
Analysis
17.4.6. SWOT
Analysis
17.4.7. Business
Strategies
17.5. AstraZeneca
17.5.1. Company
Details
17.5.2. Company
Overview
17.5.3. Product
Offerings
17.5.4. Key
Developments
17.5.5. Financial
Analysis
17.5.6. SWOT
Analysis
17.5.7. Business
Strategies
17.6. Biomunex
17.6.1. Company
Details
17.6.2. Company
Overview
17.6.3. Product
Offerings
17.6.4. Key
Developments
17.6.5. Financial
Analysis
17.6.6. SWOT
Analysis
17.6.7. Business
Strategies
17.7. Chugai
Pharmaceutical Co., Ltd
17.7.1. Company
Details
17.7.2. Company
Overview
17.7.3. Product
Offerings
17.7.4. Key
Developments
17.7.5. Financial
Analysis
17.7.6. SWOT
Analysis
17.7.7. Business
Strategies
17.8. Creative-Biolabs
17.8.1. Company
Details
17.8.2. Company
Overview
17.8.3. Product
Offerings
17.8.4. Key
Developments
17.8.5. Financial
Analysis
17.8.6. SWOT
Analysis
17.8.7. Business
Strategies
17.9. Emergent
BioSolutions Inc.
17.9.1. Company
Details
17.9.2. Company
Overview
17.9.3. Product
Offerings
17.9.4. Key
Developments
17.9.5. Financial
Analysis
17.9.6. SWOT
Analysis
17.9.7. Business
Strategies
17.10. F.
Hoffmann-La Roche Ltd
17.10.1. Company
Details
17.10.2. Company
Overview
17.10.3. Product
Offerings
17.10.4. Key
Developments
17.10.5. Financial
Analysis
17.10.6. SWOT
Analysis
17.10.7. Business
Strategies
17.11. F-star
Therapeutics Inc.
17.11.1. Company
Details
17.11.2. Company
Overview
17.11.3. Product
Offerings
17.11.4. Key
Developments
17.11.5. Financial
Analysis
17.11.6. SWOT
Analysis
17.11.7. Business
Strategies
17.12. Genentech
USA, Inc.
17.12.1. Company
Details
17.12.2. Company
Overview
17.12.3. Product
Offerings
17.12.4. Key
Developments
17.12.5. Financial
Analysis
17.12.6. SWOT
Analysis
17.12.7. Business
Strategies
17.13. Genmab
A/S
17.13.1. Company
Details
17.13.2. Company
Overview
17.13.3. Product
Offerings
17.13.4. Key
Developments
17.13.5. Financial
Analysis
17.13.6. SWOT
Analysis
17.13.7. Business
Strategies
17.14. MacroGenics,
Inc.
17.14.1. Company
Details
17.14.2. Company
Overview
17.14.3. Product
Offerings
17.14.4. Key
Developments
17.14.5. Financial
Analysis
17.14.6. SWOT
Analysis
17.14.7. Business
Strategies
17.15. Merck
KGaA
17.15.1. Company
Details
17.15.2. Company
Overview
17.15.3. Product
Offerings
17.15.4. Key
Developments
17.15.5. Financial
Analysis
17.15.6. SWOT
Analysis
17.15.7. Business
Strategies
17.16. Merus
17.16.1. Company
Details
17.16.2. Company
Overview
17.16.3. Product
Offerings
17.16.4. Key
Developments
17.16.5. Financial
Analysis
17.16.6. SWOT
Analysis
17.16.7. Business
Strategies
17.17. Pieris
17.17.1. Company
Details
17.17.2. Company
Overview
17.17.3. Product
Offerings
17.17.4. Key
Developments
17.17.5. Financial
Analysis
17.17.6. SWOT
Analysis
17.17.7. Business
Strategies
17.18. Zymeworks
17.18.1. Company
Details
17.18.2. Company
Overview
17.18.3. Product
Offerings
17.18.4. Key
Developments
17.18.5. Financial
Analysis
17.18.6. SWOT
Analysis
17.18.7. Business
Strategies
17.19. Other
Market Participants
18. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User and
Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.